Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINUTE: Shortened Infusion Times for Oncological Immunotherapies
NCT06031233Phase 4Recruiting
- Sponsor
- Isala
- Start
- Sep 2023
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, open-label trial of nivolumab, pembrolizumab, ipilimumab, durvalumab, atezolizumab and 6 more in cancer (11 arms), sponsored by Isala. Primary endpoint: Incidence of infusion related reactions. Started Sep 2023; status: recruiting.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06031233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031233.